ARWR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Arrowhead Pharmaceuticals is not a clear buy right now for a Beginner with a long-term horizon, even though the business has encouraging catalyst momentum. The stock is near resistance, insider selling is rising, and short-term pattern data points to weakness over the next week and month. For an impatient investor, this is better treated as a hold rather than an immediate buy.
ARWR is in a bullish medium-term structure with SMA_5 > SMA_20 > SMA_200, which supports an uptrend. MACD remains above zero, but the histogram is positively contracting, signaling momentum is still positive but fading. RSI_6 at 67.633 is near overbought territory and does not offer an attractive entry. Price at 78.38 is just above the pivot at 74.312 and close to first resistance at 78.327, with upside next resistance at 80.808. The current setup is extended rather than fresh, and the stock trend model suggests +0.48% next day, then -3.76% over the next week and -5.25% over the next month.
["REDEMPLO reported strong prescription growth with over 400 prescriptions written, supporting early commercial traction.", "REDEMPLO received approval in Australia for familial chylomicronemia syndrome, expanding global commercialization potential.", "JPMorgan initiated coverage with Overweight and an $88 target, citing a diversified RNAi portfolio and partnership support.", "Morgan Stanley upgraded to Overweight with a $100 target ahead of Phase 3 severe hypertriglyceridemia data in Q3, highlighting major pipeline optionality.", "BofA kept a Buy rating and raised its target to $93, reflecting a larger peak-sales view for the Redemplo-sHTG opportunity."]
["Insiders are selling, and selling activity increased 162.39% over the last month.", "The stock is trading close to resistance, limiting near-term entry attractiveness.", "MACD momentum is positive but weakening.", "RSI is elevated, suggesting the move may be extended.", "Similar pattern analysis points to downside over the next week and month.", "Net income and EPS declined sharply year over year in Q1 despite revenue growth."]
In 2026/Q1, Arrowhead posted very strong revenue growth, with revenue rising to $264.0 million, up 10,461.32% year over year, which reflects a major improvement in the top line. This is the latest quarter season. Gross margin remained at 100%, indicating very high product economics. However, net income fell to $30.8 million, down 117.80% year over year, and EPS dropped to $0.22, down 115.83% year over year, showing that profitability quality was weaker than revenue growth suggests.
Wall Street has turned more bullish recently. JPMorgan initiated Overweight at $88, Morgan Stanley upgraded to Overweight and raised its target to $100, and BofA increased its target to $93 while keeping Buy. The pro case is centered on RNAi pipeline breadth, Redemplo commercialization, and upcoming Phase 3 data that could unlock a large opportunity. The con case is that the valuation already reflects significant optimism, some uncertainty remains around future readouts, and one analyst still sees the setup as only Market Perform. Overall, the analyst trend is positive, but the stock appears to already be pricing in a lot of that optimism.
